


CK1-IN-2

Cat. No.:	HY-153866		
CAS No.:	1383376-92-8		
Molecular Formula:	C ₁₇ H ₁₂ FN ₃ O ₂		
Molecular Weight:	309.29		
Target:	Casein Kinase		
Pathway:	Cell Cycle/DNA Damage; Stem Cell/Wnt		
Storage:	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (161.66 mM; ultrasonic and warming and heat to 60°C)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	3.2332 mL	16.1661 mL	32.3321 mL
5 mM	0.6466 mL	3.2332 mL	6.4664 mL
10 mM	0.3233 mL	1.6166 mL	3.2332 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (8.08 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (8.08 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (8.08 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

CK1-IN-2 (compound Nr.4) is a potent CK1 inhibitor with an IC₅₀ values of 123, 19.8, 26.8, 74.3 nM for CK1a, CK1d, CK1e, p38a, respectively^[1].

IC₅₀ & Target

CK1a
123 nM (IC₅₀)

REFERENCES

[1]. Joris De Maeyer, et al. Casein kinase 1 inhibitors for use in the treatment of diseases related to dux4 expression such as muscular dystrophy and cancer. WO2020249717A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA